The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial
机构：[1]Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia[2]Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China大德路总院肾内科大德路总院肾内科广东省中医院[3]School of Human Movement Studies, University of Queensland, Brisbane, Australia[4]Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia[5]Center for Health Policy, Programs & Economics, University of Melbourne, Australia[6]Menzies School of Health Research, Darwin, Australia[7]Department of Renal Medicine, Fremantle Hospital, Australia[8]Department of Nephrology and Transplantation Services, University of Adelaide at Central Northern Adelaide Renal and Transplantation Services, Australia[9]Department of Nephrology, Royal Melbourne Hospital, Australia[10]George Institute, Sydney, Australia[11]Department of Renal Medicine, The Alfred Hospital, Melbourne, Australia[12]Translational Research Institute, Brisbane, Australia
Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients. Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD - 6.06 U/l, P = 0.09), or protein carbonyls (MD - 0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04). Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.
第一作者机构：[1]Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia[2]Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
通讯作者：
通讯机构：[1]Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia[4]Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia[12]Translational Research Institute, Brisbane, Australia[*1]Department of Nephrology, Princess Alexandra Hospital, Level 2, ARTS Building, Ipswich Road, Woolloongabba, Brisbane QLD 4102, Australia
推荐引用方式(GB/T 7714)：
Zhang Lei,Coombes Jeff,Pascoe Elaine M.,et al.The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial[J].REDOX REPORT.2016,21(1):14-23.doi:10.1179/1351000215Y.0000000022.
APA：
Zhang, Lei,Coombes, Jeff,Pascoe, Elaine M.,Badve, Sunil V.,Dalziel, Kim...&Johnson, David W..(2016).The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.REDOX REPORT,21,(1)
MLA：
Zhang, Lei,et al."The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial".REDOX REPORT 21..1(2016):14-23
